Table 3 HPV negative conversion rates at 12 months following Hiporfin-PDT for primary and recurrent HSIL in the female lower reproductive tract.
HPV negative conversion rates | Percentage |
|---|---|
Cervical HSIL | |
recurrent | 50% (2/4) |
primary | 92.6% (47/51) |
Vaginal HSIL | |
recurrent | 33.3% (1/3) |
primary | 54.5% (12/22) |
Multiple sites of female lower genital tract HSIL | |
recurrent | 42.8% (3/7) |
primary | 50.0% (2/4) |
